Previous 10 | Next 10 |
2024-01-04 13:29:38 ET Summary Johnson & Johnson's stock has underperformed the market, but its strong performance and secure balance sheet make it an attractive investment during uncertainty. The company's Q3 results showed solid growth, and it raised its full-year outlook, p...
2024-01-04 12:09:26 ET Summary "The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.” – Dow Jones & Co. The highes...
AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif. , Jan. 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024 . ...
2024-01-02 10:00:00 ET Summary United Therapeutics Corporation calls itself a "Public Benefit" company. The reality, it is a cynical monopolist about to lose its monopoly. If patent trolling fails, their premium to the entrant could collapse. Disclaimer . ...
2024-01-01 06:33:12 ET Summary Voya Global Advantage and Premium Opportunity Fund offers a high level of income through its portfolio of equities and dividend-paying stocks. The fund's recent performance has been disappointing, with a declining share price over the past three and ...
2024-01-01 04:44:00 ET Summary In the fourth quarter, the Dow Dogs generated mid-teens growth that resulted in the 2023 total return equaling 14.5% for the year and almost matching the Dow's return of 16.0%. With 2023 now behind us, two new Dogs of the Dow are being added for 2024...
2023-12-31 12:00:33 ET More on MCOs UnitedHealth Could Be A Combination Of Dividend Growth And Capital Appreciation In 2024 UnitedHealth: A Dividend Grower To Consider For Your Portfolio Cigna: Sentiment And Fundamentals On Their Side Catalyst Watch: Macau ga...
2023-12-31 10:26:03 ET Summary Investors welcomed double-digit increases from several companies in December, including a 16% increase from Mastercard and 14% from Broadcom. 2024 will begin with announcements of dividend increases from Chevron, Archer-Daniels Midland, Fastenal, and...
2023-12-29 11:23:28 ET Summary Shares of Viridian Therapeutics underperformed this year. Negative biotech sentiment was partly to blame, as well as Tepezza's Y/Y net sales declines, and some internal turmoil with two CEO changes. These events overshadowed many positive develop...
2023-12-28 15:06:23 ET More on AbbVie, Amgen, etc. The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Bristol Myers Squibb: Too Many Headwinds To Ignore, Despit...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-15 07:58:00 ET Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (NASDAQ: AMGN) is evidently unafraid to reward its loyal shareholders with quarterly cash payments. Just as importantly, Amgen is a recent revenue growe...
2024-07-14 06:30:00 ET Income investors don't have to settle for dividends that tread water. There are plenty of stocks to buy that offer growing dividends and are poised to keep the momentum going along with attractive dividend yields . Three Motley Fool contributors think they've ...